The study aimed to determine whether treatment with high dose ocrelizumab would provide an additional benefit in slowing disability progression.

The FDA is expected to decide on treatments for COPD, psoriasis, rare neuroendocrine tumors, and a next-generation COVID-19 vaccine.

BIIB080 is an antisense oligonucleotide therapy designed to target microtubule-associated protein tau mRNA and reduce the production of tau.

Detailed study results will be presented at an upcoming medical meeting and submitted to health authorities later this year to expand Palynziq’s label to include adolescents.

Higher prevalence ratios for misuse, prescription stimulant use disorder seen for those using amphetamines vs methylphenidate.

HealthDay News — Some commonly prescribed photosensitizing drugs increase skin cancer risk, according to a study published online March 18 in Photodermatology, Photoimmunology & Photomedicine.

The device was tested on a 47-year-old woman with quadriplegia who lost her ability to speak after a stroke. Doctors placed the brain-computer implant during surgery as part of a clinical trial, The ...

The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent Imfinzi as adjuvant ...